CoSyne Therapeutics

Rachel Watkins is Director of Experimental Biology at CoSyne Therapeutics, a company working on creating a platform for drug discovery in under-served brain diseases, based on high-quality scientific data integrated with AI and machine learning. We all know the saying ‘garbage in, garbage out’ so CoSyne have concentrated on generating the highest quality, clinically relevant data for their platform. Focusing initially on astroglial diseases, including aggressive brain cancers, CoSyne aim to develop a model that can aid drug discovery for brain diseases and beyond. Working from a biobank of patient-derived tumour cell lines, cells are grown in 3D culture to mimic tumour conditions as closely as possible e.g. hypoxia gradient. These cells are then characterised through whole-genome sequencing, single-cell transcriptomics and CRISPRi screens and these data used to power AI generated cellular simulations in order to identify biomarker / target pairings. To verify their platform’s efficiency CoSyne have identified biomarker/target pairings already established in the literature as well as many novel targets. This work has shown that the platform is working well and CoSyne are currently looking at re-purposing phase I safe but de-prioritised therapeutics towards new indications to accelerate the path of new treatments for patients in need. Rachel will be speaking at Drug Discovery 2024 on Thursday 3 October in the track ‘Target discovery and disease modelling’. Register now to catch her talk at Drug Discovery 2024: https://lnkd.in/ePmtmfN9 #braincancer #CRISPR #braindisease #singlecellsequencing #singlecell #therapeutics #cancer #tumor #braintumor #genomics #wholegenomesequencing #transcriptomics

The rapid development of CRISPR/Cas-based technologies has made it possible to modulate genomes with relative ease. 👉 Here is our team at Cosyne presenting their work on Multimodal #Genomic Screen in Patient-Derived Glioblastoma 3D Tumourspheres. A multimodal #CRISPRi platform for genetic screens in whole genome characterised, primary patient-derived 3D glioblastoma tumourspheres. This enables systematic elucidation of context-specific vulnerabilities in glioblastoma at single cell resolution.

🧬 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐚 𝐛𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐢𝐚𝐧 𝐤𝐞𝐞𝐧 𝐭𝐨 contribute to pipelines used by 1000’s of researchers globally? Join the London nf-core hackathon hosted at CoSyne Therapeutics on the 18th of March 2024    👉 Sign up, limited space here (Deadline to register 8 March): https://lnkd.in/dMjA7sgq    #CollaborativeScience #Nextflow 

🧬 Thrilled to be hosting the local node of the nf-core hackathon at CoSyne Therapeutics the 𝟏𝟖 𝐌𝐚𝐫𝐜𝐡 𝟐𝟎𝟐𝟒 in London!     👉 Sign up here, limited space (deadline 8th March): https://lnkd.in/dMjA7sgq   Nf-core is a community effort to collect a curated set of analysis pipelines built using Nextflow. There are pipelines built to analyse whole genome sequencing, proteomics and single cell RNA sequencing to name but a few. So come along and help contribute to some of these workflows!     #CollaborativeScience #Nextflow 

A metaphor for CoSyne: last year in silico, this year in the physical world. Merry Christmas from the CoSyne Team!

A metaphor for CoSyne: last year in silico, this year in the physical world. Merry Christmas from the CoSyne Team!